FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1616474014> ?p ?o ?g. }

• W1616474014 abstract "Between September 1991 and May 1996, 56 patients with refractory or relapsed acute myeloid leukemia (AML) were treated with one cycle of timed sequential chemotherapy (TSC) consisting of intermediate-dose (ID) ara-C (1.0 g/m2 every 12 h) on days 1, 2, 8, and 9, and idarubicin (IDA, 10 mg/m2) on days 3, 4, 10, and 11. The study population included 22 patients with refractory AML, 33 patients with late first relapse occurring after a first complete remission of ≥ 6 months, and 1 patient for whom the clinical course before salvage therapy was unknown. Of the 56 patients entered onto the study, 25 (45%) achieved a complete remission (CR), 8 (14%) a partial remission (PR), 11 patients (20%) were classified as treatment failure due to resistant disease, and 12 patients (21%) died within the first 42 days after the initiation of salvage therapy, mainly due to infections. Response to salvage therapy was strongly influenced by disease status with 55% of patients with late first relapse achieving a CR as compared with 32% of patients with refractoryAML. Severe myelosuppression was observed in most patients resulting in fever or documented infections in 70–90% of them whereas nonhematologic toxicity was tolerable. Among the 25 patients who achieved a CR, 6 patients received no postremission therapy, 10 patients were treated with 1 or 2 cycles of IDA (8 mg/m2) and etoposide (150 mg/m2) on days 1 to 3 as consolidation, 8 patients underwent an allogeneic or autologous bone marrow transplantation (BMT), and 1 patient was lost for follow-up. Overall, after a median follow-up of 44 months, the median remission duration is 9 months, and the median survival 9 months as well. We conclude that this chemotherapy regimen has significant antileukemic efficacy, especially in AML patients who relapsed after a durable first CR (≥ 6 months). The short duration of remission in patients not eligible for BMT, however, emphasizes the need for optimizing early postinduction therapy." @default.
• W1616474014 created "2016-06-24" @default.
• W1616474014 creator A5000205840 @default.
• W1616474014 creator A5004692376 @default.
• W1616474014 creator A5010943768 @default.
• W1616474014 creator A5017081056 @default.
• W1616474014 creator A5026626729 @default.
• W1616474014 creator A5029468510 @default.
• W1616474014 creator A5030816033 @default.
• W1616474014 creator A5038822302 @default.
• W1616474014 creator A5041847990 @default.
• W1616474014 creator A5042946623 @default.
• W1616474014 creator A5047844249 @default.
• W1616474014 creator A5064820359 @default.
• W1616474014 creator A5070264714 @default.
• W1616474014 creator A5073421855 @default.
• W1616474014 creator A5075970515 @default.
• W1616474014 creator A5078419962 @default.
• W1616474014 creator A5084457753 @default.
• W1616474014 creator A5087989374 @default.
• W1616474014 date "1998-01-01" @default.
• W1616474014 modified "2023-10-03" @default.
• W1616474014 title "Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia" @default.
• W1616474014 cites W1591796471 @default.
• W1616474014 cites W1709114039 @default.
• W1616474014 cites W1804439365 @default.
• W1616474014 cites W1819781110 @default.
• W1616474014 cites W1860795225 @default.
• W1616474014 cites W1870350942 @default.
• W1616474014 cites W1919339218 @default.
• W1616474014 cites W2008682454 @default.
• W1616474014 cites W2029007438 @default.
• W1616474014 cites W2040367419 @default.
• W1616474014 cites W2113526464 @default.
• W1616474014 cites W2266287318 @default.
• W1616474014 cites W24057889 @default.
• W1616474014 cites W3041047318 @default.
• W1616474014 cites W4211215991 @default.
• W1616474014 cites W979037046 @default.
• W1616474014 doi "https://doi.org/10.1007/978-3-642-71960-8_131" @default.
• W1616474014 hasPublicationYear "1998" @default.
• W1616474014 type Work @default.
• W1616474014 sameAs 1616474014 @default.
• W1616474014 citedByCount "0" @default.
• W1616474014 crossrefType "book-chapter" @default.
• W1616474014 hasAuthorship W1616474014A5000205840 @default.
• W1616474014 hasAuthorship W1616474014A5004692376 @default.
• W1616474014 hasAuthorship W1616474014A5010943768 @default.
• W1616474014 hasAuthorship W1616474014A5017081056 @default.
• W1616474014 hasAuthorship W1616474014A5026626729 @default.
• W1616474014 hasAuthorship W1616474014A5029468510 @default.
• W1616474014 hasAuthorship W1616474014A5030816033 @default.
• W1616474014 hasAuthorship W1616474014A5038822302 @default.
• W1616474014 hasAuthorship W1616474014A5041847990 @default.
• W1616474014 hasAuthorship W1616474014A5042946623 @default.
• W1616474014 hasAuthorship W1616474014A5047844249 @default.
• W1616474014 hasAuthorship W1616474014A5064820359 @default.
• W1616474014 hasAuthorship W1616474014A5070264714 @default.
• W1616474014 hasAuthorship W1616474014A5073421855 @default.
• W1616474014 hasAuthorship W1616474014A5075970515 @default.
• W1616474014 hasAuthorship W1616474014A5078419962 @default.
• W1616474014 hasAuthorship W1616474014A5084457753 @default.
• W1616474014 hasAuthorship W1616474014A5087989374 @default.
• W1616474014 hasConcept C121332964 @default.
• W1616474014 hasConcept C126322002 @default.
• W1616474014 hasConcept C141071460 @default.
• W1616474014 hasConcept C142424586 @default.
• W1616474014 hasConcept C2776694085 @default.
• W1616474014 hasConcept C2778041864 @default.
• W1616474014 hasConcept C2778119113 @default.
• W1616474014 hasConcept C2778729363 @default.
• W1616474014 hasConcept C2779117419 @default.
• W1616474014 hasConcept C2780775027 @default.
• W1616474014 hasConcept C2908647359 @default.
• W1616474014 hasConcept C71924100 @default.
• W1616474014 hasConcept C87355193 @default.
• W1616474014 hasConcept C90924648 @default.
• W1616474014 hasConcept C99454951 @default.
• W1616474014 hasConceptScore W1616474014C121332964 @default.
• W1616474014 hasConceptScore W1616474014C126322002 @default.
• W1616474014 hasConceptScore W1616474014C141071460 @default.
• W1616474014 hasConceptScore W1616474014C142424586 @default.
• W1616474014 hasConceptScore W1616474014C2776694085 @default.
• W1616474014 hasConceptScore W1616474014C2778041864 @default.
• W1616474014 hasConceptScore W1616474014C2778119113 @default.
• W1616474014 hasConceptScore W1616474014C2778729363 @default.
• W1616474014 hasConceptScore W1616474014C2779117419 @default.
• W1616474014 hasConceptScore W1616474014C2780775027 @default.
• W1616474014 hasConceptScore W1616474014C2908647359 @default.
• W1616474014 hasConceptScore W1616474014C71924100 @default.
• W1616474014 hasConceptScore W1616474014C87355193 @default.
• W1616474014 hasConceptScore W1616474014C90924648 @default.
• W1616474014 hasConceptScore W1616474014C99454951 @default.
• W1616474014 hasLocation W16164740141 @default.
• W1616474014 hasOpenAccess W1616474014 @default.
• W1616474014 hasPrimaryLocation W16164740141 @default.
• W1616474014 hasRelatedWork W133367400 @default.
• W1616474014 hasRelatedWork W1767685265 @default.
• W1616474014 hasRelatedWork W2150917826 @default.
• W1616474014 hasRelatedWork W2166628031 @default.

• next